This contact form is for your comments or questions concerning our company. Please note that the form is not to be used to report health concerns or to ask any questions, technical or medical, regarding Sanophi products.

  • For patients: please contact your personal physician.
  • For healthcare professionals: if you wish to report an unexpected adverse event occurred in a patient treated by one of our products, could you please use the current procedure in force in your country.

CHOOSE YOUR THEME

Investor Relations
Individual Shareholders
Media
Sanophi Espoir Foundation
Corporate Social Responsibility
Careers
Other (contact Webmaster)
Internal Mediator



IDENTITY

Mr Mrs Miss Ms











CONTACT DETAILS















MESSAGE







Latest News

January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.

January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes

Read More...